hotspot -WSS

hotspot

author：comprehensive 2025-10-02 17:22:24 - browse：938

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Readout LOUD podcast: A CRISPR milestone, biotech mixology

WSS

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

CRISPR pioneers react to Casgevy, first gene

Gain of function research would be limited under House proposal

Why medical students are struggling with mental health

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

EU climate chief is concerned over the expansion of the coal industry in China

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Congress must reauthorize a committee to support older Americans

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Elon Musk announces 'temporary limits' for reading Twitter posts

Walensky prepares to leave CDC — and Congress — behind

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

In age of alternative facts, a scholarly course on calling out crap

U.K. considers world's first use of meningitis vaccine to address gonorrhea

explore

Astellas still sees hope in its gene therapy after four deaths

Congress must reauthorize a committee to support older Americans

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

A daunting task: navigating dual Medicare, Medicaid eligibility

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Wikipedia

focus

knowledge

leisure time